Ray Liu, PhD, is the Head of Statistical Innovation and Consultation at Takeda Pharmaceutical Company. Dr. Liu received his BS and MA degrees from the National Taiwan University, Taiwan and his PhD from Columbia University, USA. He currently oversees the development of novel methodologies and provides statistical consultation and project support to various functional areas in pharmaceutical R&D, including Discovery, CMC, Translational Research, and Outcome Research. Dr. Liu was the conference chair of the 38th and 39th Midwest Biopharmaceutical Statistics Workshop. He is the author of more than 30 statistical and scientific articles and book chapters, editor of the Springer book “Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Analytics”, frequent conference speaker on Big Data and the member of the ASA, PSTC Stats working group, IQ consortium, and NCBLF.   Yi Tsong, PhD, is the Division Director of Biometrics at the Food and Drug Administration (FDA). He specializes in post-marketing risk assessment, drug manufacturing process control and quality assurance, active control non-inferiority/equivalence tests, adaptive design, bioequivalence and analytical biosimilarity, and QTc trials, and has published more than 90 articles in these areas. Dr. Tsong received his PhD in Statistics from the University of North Carolina at Chapel Hill, USA and did his post-doctoral training in cardiovascular prevention and biostatistics at Northwestern University Medical School, USA. He has served as the Treasurer, Board Director, and President of the International Chinese Statistical Association and currently serves as Associate Editor of Statistics in Medicine, the Journal of Biopharmaceutical Statistics,and Pharmaceutical Statistics.

• Part I: Specification and Sampling Acceptance Tests.- Statistical Considerations in Setting Quality Specification Limits Using Quality Data.- Counting Test and Parametric Two One-Sided Tolerance Interval Test for Content Uniformity Using Large Sample Sizes.- Part II: Analytical Biosimilar and Process Validation.- Sample Size Consideration for Equivalent Test of Tier-1 Quality Attributes for Analytical Biosimilarity Assessment.- A Probability Based Equivalence Test of NIR Versus HPLC Analytical Methods in a Continuous Manufacturing Process Validation Study.- A Further Look at the Current Equivalence Test for Analytical Similarity Assessment.- Shiny Tools for Sample Size Calculation in Process Performance Qualification of Large Molecules.- Part III: Continuous Process.- Risk Evaluation of Registered Specifications and Internal Release Limits Using a Bayesian Approach.- Development of Statistical Computational Tools Through Pharmaceutical Drug Development and Manufacturing Life Cycle.- Application of Advanced Statistical Tools to Achieve Continuous Analytical Verification: A Risk Assessment Case of the Impact of Analytical Method Performance on Process Performance Using a Bayesian Approach.- Part IV: Clinical Trial Design and Analysis.- Exact Inference for Adaptive Group Sequential Designs.- A Novel Framework for Bayesian Response-Adaptive Randomization.- Sample Size Determination Under Non-proportional Hazards.- Adaptive Three-Stage Clinical Trial Design for a Binary Endpoint in the Rare Disease Setting.- Part V: Biomarker-Driven Trial Design.- Clinical Trial Designs to Evaluate Predictive Biomarkers: What’s Being Estimated?.- Biomarker Enrichment Design Considerations in Oncology Single Arm Studies.- Challenges of Bridging Studies in Biomarker Driven Clinical Trials: The Impact of Companion Diagnostic Device Performance on Clinical Efficacy.- Part VI: Application of Novel Data Modality.- Parallel-Tempered Feature Allocation for Large-Scale Tumor Heterogeneitywith Deep Sequencing Data.- Analysis of T-Cell Immune Responses as Measured by Intracellular Cytokine Staining with Application to Vaccine Clinical Trials.- Project Data Sphere and the Applications of Historical Patient Level Clinical Trial Data in Oncology Drug Development.- Novel Test for the Equality of Continuous Curves with Homoscedastic or Heteroscedastic Measurement Errors.- Quality Control Metrics for Extraction-Free Targeted RNA-Seq Under a Compositional Framework.- Part VII: Omics Data Analysis.- Leveraging Omics Biomarker Data in Drug Development: With a GWAS Case Study.- A Simulation Study Comparing SNP Based Prediction Models of Drug Response.

Ray Liu, PhD, is the Head of Statistical Innovation and Consultation at Takeda Pharmaceutical Company. Dr. Liu received his BS and MA degrees from the National Taiwan University, Taiwan and his PhD from Columbia University, USA. He currently oversees the development of novel methodologies and provides statistical consultation and project support to various functional areas in pharmaceutical R&D, including Discovery, CMC, Translational Research, and Outcome Research. Dr. Liu was the conference chair of the 38th and 39th Midwest Biopharmaceutical Statistics Workshop. He is the author of more than 30 statistical and scientific articles and book chapters, editor of the Springer book “Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Analytics”, frequent conference speaker on Big Data and the member of the ASA, PSTC Stats working group, IQ consortium, and NCBLF.   Yi Tsong, PhD, is the Division Director of Biometrics at the Food and Drug Administration (FDA). He specializes in post-marketing risk assessment, drug manufacturing process control and quality assurance, active control non-inferiority/equivalence tests, adaptive design, bioequivalence and analytical biosimilarity, and QTc trials, and has published more than 90 articles in these areas. Dr. Tsong received his PhD in Statistics from the University of North Carolina at Chapel Hill, USA and did his post-doctoral training in cardiovascular prevention and biostatistics at Northwestern University Medical School, USA. He has served as the Treasurer, Board Director, and President of the International Chinese Statistical Association and currently serves as Associate Editor of Statistics in Medicine, the Journal of Biopharmaceutical Statistics,and Pharmaceutical Statistics.

• Part I: Specification and Sampling Acceptance Tests.- Statistical Considerations in Setting Quality Specification Limits Using Quality Data.- Counting Test and Parametric Two One-Sided Tolerance Interval Test for Content Uniformity Using Large Sample Sizes.- Part II: Analytical Biosimilar and Process Validation.- Sample Size Consideration for Equivalent Test of Tier-1 Quality Attributes for Analytical Biosimilarity Assessment.- A Probability Based Equivalence Test of NIR Versus HPLC Analytical Methods in a Continuous Manufacturing Process Validation Study.- A Further Look at the Current Equivalence Test for Analytical Similarity Assessment.- Shiny Tools for Sample Size Calculation in Process Performance Qualification of Large Molecules.- Part III: Continuous Process.- Risk Evaluation of Registered Specifications and Internal Release Limits Using a Bayesian Approach.- Development of Statistical Computational Tools Through Pharmaceutical Drug Development and Manufacturing Life Cycle.- Application of Advanced Statistical Tools to Achieve Continuous Analytical Verification: A Risk Assessment Case of the Impact of Analytical Method Performance on Process Performance Using a Bayesian Approach.- Part IV: Clinical Trial Design and Analysis.- Exact Inference for Adaptive Group Sequential Designs.- A Novel Framework for Bayesian Response-Adaptive Randomization.- Sample Size Determination Under Non-proportional Hazards.- Adaptive Three-Stage Clinical Trial Design for a Binary Endpoint in the Rare Disease Setting.- Part V: Biomarker-Driven Trial Design.- Clinical Trial Designs to Evaluate Predictive Biomarkers: What’s Being Estimated?.- Biomarker Enrichment Design Considerations in Oncology Single Arm Studies.- Challenges of Bridging Studies in Biomarker Driven Clinical Trials: The Impact of Companion Diagnostic Device Performance on Clinical Efficacy.- Part VI: Application of Novel Data Modality.- Parallel-Tempered Feature Allocation for Large-Scale Tumor Heterogeneitywith Deep Sequencing Data.- Analysis of T-Cell Immune Responses as Measured by Intracellular Cytokine Staining with Application to Vaccine Clinical Trials.- Project Data Sphere and the Applications of Historical Patient Level Clinical Trial Data in Oncology Drug Development.- Novel Test for the Equality of Continuous Curves with Homoscedastic or Heteroscedastic Measurement Errors.- Quality Control Metrics for Extraction-Free Targeted RNA-Seq Under a Compositional Framework.- Part VII: Omics Data Analysis.- Leveraging Omics Biomarker Data in Drug Development: With a GWAS Case Study.- A Simulation Study Comparing SNP Based Prediction Models of Drug Response.

Ray Liu, PhD, is the Head of Statistical Innovation and Consultation at Takeda Pharmaceutical Company. Dr. Liu received his BS and MA degrees from the National Taiwan University, Taiwan and his PhD from Columbia University, USA. He currently oversees the development of novel methodologies and provides statistical consultation and project support to various functional areas in pharmaceutical R&D, including Discovery, CMC, Translational Research, and Outcome Research. Dr. Liu was the conference chair of the 38th and 39th Midwest Biopharmaceutical Statistics Workshop. He is the author of more than 30 statistical and scientific articles and book chapters, editor of the Springer book “Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Analytics”, frequent conference speaker on Big Data and the member of the ASA, PSTC Stats working group, IQ consortium, and NCBLF.   Yi Tsong, PhD, is the Division Director of Biometrics at the Food and Drug Administration (FDA). He specializes in post-marketing risk assessment, drug manufacturing process control and quality assurance, active control non-inferiority/equivalence tests, adaptive design, bioequivalence and analytical biosimilarity, and QTc trials, and has published more than 90 articles in these areas. Dr. Tsong received his PhD in Statistics from the University of North Carolina at Chapel Hill, USA and did his post-doctoral training in cardiovascular prevention and biostatistics at Northwestern University Medical School, USA. He has served as the Treasurer, Board Director, and President of the International Chinese Statistical Association and currently serves as Associate Editor of Statistics in Medicine, the Journal of Biopharmaceutical Statistics,and Pharmaceutical Statistics.

• Part I: Specification and Sampling Acceptance Tests.- Statistical Considerations in Setting Quality Specification Limits Using Quality Data.- Counting Test and Parametric Two One-Sided Tolerance Interval Test for Content Uniformity Using Large Sample Sizes.- Part II: Analytical Biosimilar and Process Validation.- Sample Size Consideration for Equivalent Test of Tier-1 Quality Attributes for Analytical Biosimilarity Assessment.- A Probability Based Equivalence Test of NIR Versus HPLC Analytical Methods in a Continuous Manufacturing Process Validation Study.- A Further Look at the Current Equivalence Test for Analytical Similarity Assessment.- Shiny Tools for Sample Size Calculation in Process Performance Qualification of Large Molecules.- Part III: Continuous Process.- Risk Evaluation of Registered Specifications and Internal Release Limits Using a Bayesian Approach.- Development of Statistical Computational Tools Through Pharmaceutical Drug Development and Manufacturing Life Cycle.- Application of Advanced Statistical Tools to Achieve Continuous Analytical Verification: A Risk Assessment Case of the Impact of Analytical Method Performance on Process Performance Using a Bayesian Approach.- Part IV: Clinical Trial Design and Analysis.- Exact Inference for Adaptive Group Sequential Designs.- A Novel Framework for Bayesian Response-Adaptive Randomization.- Sample Size Determination Under Non-proportional Hazards.- Adaptive Three-Stage Clinical Trial Design for a Binary Endpoint in the Rare Disease Setting.- Part V: Biomarker-Driven Trial Design.- Clinical Trial Designs to Evaluate Predictive Biomarkers: What’s Being Estimated?.- Biomarker Enrichment Design Considerations in Oncology Single Arm Studies.- Challenges of Bridging Studies in Biomarker Driven Clinical Trials: The Impact of Companion Diagnostic Device Performance on Clinical Efficacy.- Part VI: Application of Novel Data Modality.- Parallel-Tempered Feature Allocation for Large-Scale Tumor Heterogeneitywith Deep Sequencing Data.- Analysis of T-Cell Immune Responses as Measured by Intracellular Cytokine Staining with Application to Vaccine Clinical Trials.- Project Data Sphere and the Applications of Historical Patient Level Clinical Trial Data in Oncology Drug Development.- Novel Test for the Equality of Continuous Curves with Homoscedastic or Heteroscedastic Measurement Errors.- Quality Control Metrics for Extraction-Free Targeted RNA-Seq Under a Compositional Framework.- Part VII: Omics Data Analysis.- Leveraging Omics Biomarker Data in Drug Development: With a GWAS Case Study.- A Simulation Study Comparing SNP Based Prediction Models of Drug Response.